XML 75 R62.htm IDEA: XBRL DOCUMENT
v3.22.2

Commitments and contingencies - Narrative (Details) - USD ($) $ in Thousands |  | 1 Months Ended | 6 Months Ended |  |  |  |
--- | --- | --- | --- | --- | --- | --- | ---
Apr. 29, 2020 | Aug. 31, 2021 | Dec. 31, 2019 | May 31, 2019 | Aug. 31, 2018 | Jun. 30, 2022 | Jul. 31, 2022 | Dec. 31, 2021 | May 29, 2020 | Jun. 30, 2016
Other Commitments |  |  |  |  |  |  |  |  |  |
Accrued royalties |  |  |  |  |  | $ 34,230 |  | $ 35,679 |  |
Akcea |  |  |  |  |  |  |  |  |  |
Other Commitments |  |  |  |  |  |  |  |  |  |
Upfront licensing fee |  |  |  |  | $ 12,000 |  |  |  |  |
Milestone payments |  | $ 4,000 |  |  |  |  |  |  |  |
Akcea | Maximum |  |  |  |  |  |  |  |  |  |
Other Commitments |  |  |  |  |  |  |  |  |  |
Milestone payments |  | $ 4,000 |  |  |  |  |  |  |  |
Censa |  |  |  |  |  |  |  |  |  |
Other Commitments |  |  |  |  |  |  |  |  |  |
Asset acquisition, development and regulatory milestones |  |  |  |  |  |  |  |  | $ 109,000 |
Asset acquisition, initial milestone |  |  |  |  |  |  |  |  | 30,000 |
Censa | Maximum |  |  |  |  |  |  |  |  |  |
Other Commitments |  |  |  |  |  |  |  |  |  |
Asset acquisition, milestone, amount |  |  |  |  |  |  |  |  | 217,500 |
Asset acquisition, net sales milestone |  |  |  |  |  |  |  |  | $ 160,000 |
Agilis Merger Agreement | Akcea |  |  |  |  |  |  |  |  |  |
Other Commitments |  |  |  |  |  |  |  |  |  |
Milestone payments |  |  | $ 4,000 | $ 6,000 |  |  |  |  |  |
SMA License Agreement | SMA Foundation |  |  |  |  |  |  |  |  |  |
Other Commitments |  |  |  |  |  |  |  |  |  |
Royalty expense |  |  |  |  |  | 16,200 |  |  |  |
Royalty payments |  |  |  |  |  | 12,100 |  |  |  |
Accrued royalties |  |  |  |  |  | 4,100 |  |  |  |
SMA License Agreement | SMA Foundation | Maximum |  |  |  |  |  |  |  |  |  |
Other Commitments |  |  |  |  |  |  |  |  |  |
Potential royalty payments due on net product sales |  |  |  |  |  | 52,500 |  |  |  |
Agilis |  |  |  |  |  |  |  |  |  |
Other Commitments |  |  |  |  |  |  |  |  |  |
Development milestone payments which the entity is obligated to pay | $ 40,000 |  |  |  |  | 40,000 |  |  |  |
Development milestone obligation payments made |  |  |  |  |  | $ 2,400 |  |  |  |
Agilis | Minimum |  |  |  |  |  |  |  |  |  |
Other Commitments |  |  |  |  |  |  |  |  |  |
Product sales (as a percent) |  |  |  |  |  | 2.00% |  |  |  |
Agilis | Maximum |  |  |  |  |  |  |  |  |  |
Other Commitments |  |  |  |  |  |  |  |  |  |
Development milestone payments which the entity is obligated to pay |  |  |  |  |  | $ 60,000 |  |  |  |
Priority review voucher amount |  |  |  |  |  | 535,000 |  |  |  |
Net sales amount |  |  |  |  |  | $ 150,000 |  |  |  |
Product sales (as a percent) |  |  |  |  |  | 6.00% |  |  |  |
Development milestone payment obligations, net of cancellation and forfeiture |  |  |  |  |  | $ 20,000 |  |  |  |
Contingent liability, milestone, potential achievements, priority review voucher amount, net of cancellation and forfeiture |  |  |  |  |  | 361,000 |  |  |  |
Agilis | Rights Exchange Agreement |  |  |  |  |  |  |  |  |  |
Other Commitments |  |  |  |  |  |  |  |  |  |
Contingent liability cancellation and forfeiture of potential milestone payments | 174,000 |  |  |  |  |  |  |  |  |
Development milestone payment obligations, cancellation and forfeiture | 37,600 |  |  |  |  |  |  |  |  |
Contingent liability, cancellation and forfeiture | $ 211,600 |  |  |  |  |  |  |  |  |
BioElectron | Maximum |  |  |  |  |  |  |  |  |  |
Other Commitments |  |  |  |  |  |  |  |  |  |
Development milestone payments which the entity is obligated to pay |  |  |  |  |  | 200,000 |  |  |  |
Marathon | Agilis Merger Agreement |  |  |  |  |  |  |  |  |  |
Other Commitments |  |  |  |  |  |  |  |  |  |
Development milestone payments which the entity is obligated to pay |  |  |  |  |  | 50,000 |  |  |  |
Net product revenue | Wellcome trust |  |  |  |  |  |  |  |  |  |
Other Commitments |  |  |  |  |  |  |  |  |  |
Development milestone payments which the entity is obligated to pay |  |  |  |  |  |  |  |  |  | $ 800
Net product revenue | Wellcome trust | Maximum |  |  |  |  |  |  |  |  |  |
Other Commitments |  |  |  |  |  |  |  |  |  |
Development milestone payments which the entity is obligated to pay |  |  |  |  |  | $ 22,400 |  |  |  |
Subsequent Event [Member] | Agilis |  |  |  |  |  |  |  |  |  |
Other Commitments |  |  |  |  |  |  |  |  |  |
Development milestone payment obligations |  |  |  |  |  |  | $ 50,000 |  |  |

X
- Definition Asset Acquisition, Development And Regulatory Milestones + References No definition available. + Details
Name: | ptct_AssetAcquisitionDevelopmentAndRegulatoryMilestones
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Asset Acquisition, Initial Milestone + References No definition available. + Details
Name: | ptct_AssetAcquisitionInitialMilestone
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Asset Acquisition, Milestone, Amount + References No definition available. + Details
Name: | ptct_AssetAcquisitionMilestoneAmount
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Asset Acquisition, Net Sales Milestone + References No definition available. + Details
Name: | ptct_AssetAcquisitionNetSalesMilestone
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Contingent Liability, Cancellation and Forfeiture + References No definition available. + Details
Name: | ptct_ContingentLiabilityCancellationAndForfeiture
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Contingent Liability cancellation and forfeiture, Milestone, Potential Achievements, Priority Review Voucher Amount + References No definition available. + Details
Name: | ptct_ContingentLiabilityCancellationAndForfeitureMilestonePotentialAchievementsPriorityReviewVoucherAmount
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Contingent Liability, Milestone, Potential Achievements, Net Sales Milestone And Regulatory Approval + References No definition available. + Details
Name: | ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount + References No definition available. + Details
Name: | ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount, Net of Cancellation and Forfeiture + References No definition available. + Details
Name: | ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Contingent Liability, Milestone, Potential Achievements, Product Sales Percentage + References No definition available. + Details
Name: | ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage
Namespace Prefix: | ptct_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of development milestone obligation payments made during the period. + References No definition available. + Details
Name: | ptct_DevelopmentMilestoneObligationPaymentsMade
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the development milestones payments which the entity is obligated to pay under certain contractual agreements. + References No definition available. + Details
Name: | ptct_DevelopmentMilestonePaymentObligations
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Development Milestone Payment Obligations, Cancellation and Forfeiture + References No definition available. + Details
Name: | ptct_DevelopmentMilestonePaymentObligationsCancellationAndForfeiture
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the development milestones payments which the entity is obligated to pay under certain contractual agreements. + References No definition available. + Details
Name: | ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Development Milestone Payment Obligations, net of cancellation and forfeiture + References No definition available. + Details
Name: | ptct_DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone payment which the entity is obliged to pay upon regulatory approval + References No definition available. + Details
Name: | ptct_MilestonePotentialAchievementsRegulatoryApproval
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of potential royalties due on worldwide net product sales per terms of the collaboration agreement. + References No definition available. + Details
Name: | ptct_PotentialRoyaltiesDueNetProductSales
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront Licensing Fee + References No definition available. + Details
Name: | ptct_UpfrontLicensingFee
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_AccruedRoyaltiesCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | us-gaap_OtherCommitmentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of cash paid for royalties during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (g) -URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585 + Details
Name: | us-gaap_PaymentsForRoyalties
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.3) -URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227 + Details
Name: | us-gaap_RoyaltyExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=ptct_AkceaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ptct_CensaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_NoncollaborativeArrangementTransactionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ptct_SmaFoundationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ptct_RightsExchangeAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=ptct_BioElectronMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=ptct_MarathonPharmaceuticalsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ptct_WellcomeTrustLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |